A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) (clinicaltrials.gov) - Sep 23, 2026 - P3 | N=190 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Trial primary completion date: Mar 2026 ➔ Feb 2027
Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ROS1
|